Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.14645 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Eirik Aaseth und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Innlandet Hospital Trust, Elverum, Norway. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Heart Diseases, Heart Failure. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Nuclear Medicine.
Abstract (Originalsprache)
Aims
Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by increased wall thickness, diastolic dysfunction and progressive heart failure symptoms. The disease may infiltrate the conduction system leading to conduction disturbances requiring an implantation of permanent cardiac pacemaker (PM), but the extent is unknown. Here, we report the prevalence of ATTR-CM in patients ≥65 years with PM. Methods and results In this prospective, cross-sectional single-centre study patients were recruited from our out-patient pacemaker clinic. Eligibility criteria were age above 65 years, permanent cardiac pacemaker and competent to give informed consent. Patients underwent echocardiography at the pacemaker visit and were referred to 99mTc-DPD-scintigraphy (DPD) and blood samples if septum thickness was ≥12 mm, defined as left ventricular hypertrophy (LVH). Fifty eight of the 128 patients had LVH on echocardiography. Eleven patients had a DPD-scintigraphy based diagnosis of ATTR-CM, which represent 19% of patients with LVH and 9% of the total cohort. Patients diagnosed with ATTR-CM had higher concentrations of cardiac biomarkers (P < 0.001), higher E/E′ (P = 0.001), and lower global longitudinal strain (P = 0.003) on echocardiography and more heart failure symptoms (P = 0.001).
Conclusions
The prevalence of ATTR-CM in elderly patients with PM and LVH on echocardiography was 19%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Innlandet Hospital Trust, Elverum, Norway.
- Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.
Förderung
- Department of Nuclear Medicine
Zitieren
APA
Aaseth, E., & Christiansen, J. R. (2024). Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients. ESC Heart Failure. https://doi.org/10.1002/ehf2.14645
Vancouver
Aaseth E, Christiansen JR. Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients. ESC Heart Failure. 2024. doi:10.1002/ehf2.14645
BibTeX
@article{Aaseth2024,
author = {Aaseth, Eirik and Christiansen, Jon R},
title = {Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.14645}
}
EUVIMED